BMO Capital Reiterates Outperform Rating on Abbvie (ABBV) as I&I Portfolio Sees New Avenues for Growth in 2025
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $208.00 price target on Abbvie (NYSE: ABBV).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
